Dexmedetomidine as an Adjunct to Fentanyl for Term Neonates on Mechanical Ventilation
Status:
COMPLETED
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Despite well conducted studies on pain management in mechanically ventilated neonates, there is still a need for exploration of appropriate and accurate pharmacological management strategies for this ongoing pain, and assessment of the clinical impact of the used drugs for analgesia and sedation. Opioids, such as fentanyl, are frequently used for analgesia and sedation in mechanically ventilated neonates with their short- and long-term adverse consequences Dexmedetomidine (DEX) is a specific alpha2 adrenergic agonist with promising data in NICU. Data exist that DEX recipient neonates require less adjunct sedation, experience less respiratory depression, less clinically significant hemodynamic effects, quicker establishment of enteral feeds and they could be extubated whilst on DEX infusion.
In the current study, we aim to reduce fentanyl doses on mechanical ventilated neonates after adding DEX